Drugs / anti-CD19 CAR NK cells
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05673447 | Mar → Dec 2023 | diffuse large B-cell lymphoma | Changhai Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT03690310 | Mar 2019 → Nov 2020 | B-cell non-Hodgkin lymphoma | Allife Medical Science and Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT06827782 | Mar 2025 → Dec 2026 expected | central nervous system non-hodgkin lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06421701 | Aug 2024 → Aug 2025 | systemic lupus erythematosus | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT06464679 | Jun 2024 → Dec 2025 overdue | autoimmune disease | Changhai Hospital | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06631040 | Dec 2024 → Nov 2026 expected | acute lymphoblastic leukemia | Shahid Beheshti University of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti CD19 CAR NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06631040 ↗ |
| Modality | Cell therapy | “Anti-CD19 CAR NK cells” NCT03690310 ↗ |
| Route | Other | “Anti-CD19 CAR NK Cells injection” NCT03690310 ↗ |
| Target | CD19 | “Anti-CD19 CAR NK cells” NCT03690310 ↗ |